Restoring Lives
One Story At A Time

We are Assertio — an assertive, energetic, and empathetic pharmaceutical company built around the mission of advancing patient care. Formerly known as Depomed, we have transformed our company with a current focus on three FDA-approved products in our core areas of neurology, orphan, and specialty medicines, as we continue to identify, license, and develop new products that offer enhanced options for patients who may be underserved by existing therapies. More

In the News

November 8, 2018

Assertio Therapeutics Announces Third-Quarter 2018 Financial ResultsRead More

October 29, 2018

Assertio Therapeutics Announces the Appointment of Daniel A. Peisert as Senior Vice President and Chief Financial Officer; Current CFO Phil B. Donenberg to Retire November 30, 2018Read More

October 17, 2018

Assertio Therapeutics to Participate in Upcoming Investor ConferencesRead More

More News